New Leukemia Therapy Research Released; Westat Provided Data Management, Study Oversight
Data on new leukemia therapy research has been released in a recent issue of Leukemia and Lymphoma Journal: Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Westat staff members Kathleen Tiefenwerth, Susan Denton, Georgine Price, Whitney Smith, and Christine Anderson assisted with data management and study oversight.
While the treatment studied demonstrated some clinical activity, there was an increase in a common chemotherapy side effect, so the study was terminated in the second phase of the study. Research suggests a lower dose or truncated dosing regimen may yield benefits without these toxicities.